



JFL LIFE SCIENCES LIMITED

November 14, 2024

To
The General Manager (Listing)
National Stock Exchange of India Limited
5th Floor, Exchange Plaza,
Plot No. c/1, G Block, Bandra-Kurla Complex, Bandra (East)
Mumbai-400051

Respected Sir(s),

SUB: - OUTCOME OF BOARD OF DIRECTORS MEETING

NSE SYMBOL: JFLIFE; ISIN: INE0LA901015

With reference to the cited subject we hereby submit the following outcome of meeting of the Board of Directors of the Company held on **Thursday, November 14, 2024** at the Registered Office of the Company **commenced at 02:00 PM** and **concluded at 03:00 P.M:**

1. Considered and approved the audited Standalone Financial results, Statement of Assets & Liabilities and Cash Flow Statement for six months ended September 30, 2024 along with the Audit Report.

This is for your kind information and records.

Thanking You.

Yours Truly,

For JFL LIFE SCIENCES LIMITED

SMIRAL ASHWINKUMAR PATEL
Managing Director
DIN: 00769486

Encl: A/a

Doshi Doshi & Co

Chartered Accountants

A908, 9th Floor, Venus Stratum,
West Wing, Venus Grounds,
Nehrunagar, Ahmedabad – 380015
Phone :- +91 91674 04303
Email :- chintan@ddco.in

Independent Auditor's Report on financial results for half year ended 30th September 2024 of the company pursuant to the Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015.

To
the Board of Directors
JFL Life Sciences Limited

Opinion

We have audited the financial results of JFL Life Sciences Limited ("the Company") for the half year ended 30th September 2024 (the 'Statement'), attached herewith being submitted by the Company pursuant to the requirement of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 as amended ('Listing Regulations'),

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Statement :

- (i) Is presented in accordance with the requirements of Regulation 33 of the listing regulations in this regards; and
- (ii) and give a true and fair view in conformity with the Accounting Standards prescribed under section 133 of the Act read with the Companies (Accounting Standards) Rules, 2021 and other accounting principles generally accepted in India, of the net profit and other financial information of the Company for the half year ended 30th September 2024.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the financial results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules there under and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Responsibilities of Management and Those Charged with Governance for the Financial results

This statement have been prepared on the basis of the half yearly financial statements. The Company's Board of Directors are responsible for the preparation and presentation of this statement that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the accounting principles generally accepted in India, including accounting standards specified under Section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other



Doshi Doshi & Co

Chartered Accountants

A908, 9th Floor, Venus Stratum,
West Wing, Venus Grounds,
Nehrunagar, Ahmedabad – 380015
Phone :- +91 91674 04303
Email :- chintan@ddco.in

irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial results, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial results

Our objectives are to obtain reasonable assurance about whether the financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- a) Identify and assess the risks of material misstatement of the financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- b) Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial results in place and the operating effectiveness of such controls.
- c) Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- d) Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.



Doshi Doshi & Co

Chartered Accountants

A908, 9th Floor, Venus Stratum,
West Wing, Venus Grounds,
Nehrunagar, Ahmedabad – 380015
Phone :- +91 91674 04303
Email :- chintan@ddco.in

- e) Evaluate the overall presentation, structure and content of the financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

For **Doshi Doshi & Co**,
Chartered Accountants
Firm Registration No.: 153683W



Chintan Doshi

Partner

Membership No.:158931

UDIN: 24158931BKAUVM7363



Place: Ahmedabad

Date: November 14, 2024

JFL Life Sciences Limited

CIN : L24230GJ2010PLC060417

Reg Office :- 309, SATYAM MALL, OPP. SAMAN COMPLEX, NR. VISHWESHWAR MAHADEV MANDIR, SETTELITE, AHMEDABAD 380015
Tele No. +91-93772 95575, Email id :- info@jfllifesciences.com, www.jfllifesciences.com

AUDITED FINANCIAL RESULTS FOR THE HALF YEAR ENDED 30 SEPTEMBER, 2024

SR.NO.	PARTICULARS.	6 Months Ended on	6 Months Ended on	6 Months Ended on	Year Ended on
		30.09.2024 (AUDITED)	31.03.2024 (Refer Note 5)	30.09.2023 (UNAUDITED)	31.03.2024 (AUDITED)
	INCOMES				
I	Revenue from Operations	4,905.59	2,730.37	1,924.42	4,654.79
II	Other Income	0.44	44.29	8.09	52.37
III	Total Income (I + II)	4,906.03	2,774.66	1,932.50	4,707.16
IV	EXPENSES.				
(a)	Cost of materials consumed	4,281.90	2,448.85	1,374.37	3,823.22
(b)	Purchase of Stock in Trade.	-	-	-	-
(c)	Changes of Inventories of Finished Goods, Work in Progress, Work in Trade.	(67.56)	(136.41)	198.87	62.46
(d)	Employee benefits expense	96.30	157.56	43.75	201.31
(e)	Finance Cost	53.52	(14.92)	97.53	82.61
(f)	Depreciation and Amortisation Expenses	47.81	23.33	20.93	44.27
(g)	Other Expenses	48.63	45.28	68.02	113.30
	TOTAL EXPENSES (IV (a to g))	4,460.61	2,523.70	1,803.46	4,327.17
V	Profit/(Loss) before Exceptional Items and Tax. (III-IV)	445.42	250.95	129.04	379.99
VI	Exceptional Items. & Extraordinary Item	-	-	-	-
VII	Profit/ (Loss) Before Tax. (V-VI)	445.42	250.95	129.04	379.99
VIII	TAX EXPENSES.				
(a)	Current Tax.	109.15	60.12	19.40	79.52
(b)	Deffered Tax.	2.96	(40.27)	9.96	(30.31)
	Total Tax Expenses.	112.11	19.85	29.36	49.21
IX	NET PROFIT / (LOSS) FOR THE PERIOD	336.27	231.11	99.68	330.79
X	Paid up Equity Share Capital (Amount in lacs)	1,099.84	1,099.84	1,099.84	1,099.84
	Rs. 10 Face value per share)	Rs. 10/-	Rs. 10/-	Rs. 10/-	Rs. 10/-
XI	Other Equity Capital (Reserve & Surplus)				
XII	Earning Per Share (In Rupees) from				
(i)	Basic.	3.06	2.10	1.19	3.01
(ii)	Diluted.	3.06	2.10	1.19	3.01

NOTES:

- 1 These financial result were reviewed by the Board of Directors and thereafter have been approved by the board of directors at its meeting held on Thursday, November 14, 2024. The Statutory Auditors have carried out Audit of the financial result for the half year ended on September 30, 2024.
- 2 The statement has been prepared in accordance with the recognition and mesaurment principles laid down in the Relevant Accounting Standard prescribed under section 133 of the Companies Act, 2013 read with the relevant rules thereunder and the terms of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015, as amended.
- 3 As per MCA Notification dated 16th Feb 2015, Companies whose shares are listed on the SME Exchange as referred to in Chapter XB of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2009 are exempted from the Compulsory requirement of adoption of Ind AS for the preparation of Financial Results,
- 4 Company has only one reportable segment - Pharmaceuticals Manufacturing
- 5 The financial results for the six month ended September 30, 2024 are balancing figures between audited results for the full financial year and the published year to date figure upto half yearly ended March 31, 2024.
- 6 Figures for the previous period have been regrouped/ rearranged/ reclassified wherever considered necessary to correspond with the current period's classification/group

For JFL Life Sciences Limited

Smiral A. Patel

Director

DIN : 00769486

Dated : 14, November 2024

Place : Ahmedabad



JFL Life Sciences Limited

CIN : L24230GJ2010PLC060417

Reg Office :- 309, SATYAM MALL, OPP. SAMAN COMPLEX, NR. VISHWESHWAR MAHADEV MANDIR, SETTELITE,
AHMEDABAD 380015


Tele No. +91-93772 95575, Email id :- info@jfllifesciences.com, www.jfllifesciences.com

CASH FLOW STATEMENT FOR THE PERIOD ENDED 30TH SEPTEMBER, 2024

(Rs.In Lakhs)

Particulars	For the period ended 30 September 2024	For the Year ended 31 March 2024
A. CASH FLOW FROM OPERATING ACTIVITIES		
Profit before tax	445.42	379.99
Finance cost	53.52	82.61
Depreciation and amortisation income	47.81	44.27
Provision for Gratuity	0.85	1.14
Interest income	-	(2.64)
Operating profit before working capital changes	547.60	505.37
Movements in working capital:		
Adjusted for (Increase)/Decrease in operating assets		
Long-Term Loans and advances	(2.06)	18.17
Inventories	(241.08)	(310.91)
Trade Receivables	(2,485.83)	(267.25)
Short Term Loans and advances	(102.98)	376.52
Other Current Assets	2.73	-
Adjusted for Increase/(Decrease) in operating liabilities:		
Trade Payables	1,579.54	242.13
Other Current Liabilities	448.63	277.37
Cash generated (used in)/from operations	(253.44)	841.39
Income tax paid	(171.02)	(5.67)
Net cash flow generated (used in)/from operating activities (A)	(424.47)	835.72
B. CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of property plant & equipment and intangible asset	(16.67)	(609.58)
Interest received	-	2.64
Proceeds from fixed deposits	40.70	-
Net cash flow from/(used in) investing activities (B)	24.03	(606.94)
C. CASH FLOW FROM FINANCING ACTIVITIES		
Issuing share Capital including share premium	-	-
Repayment of long and short-term borrowings	479.34	(148.69)
Finance cost	(53.52)	(82.61)
Net cash flow from / (used in) financing activities (C)	425.82	(231.30)
Net increase / (decrease) in cash and cash equivalents (A+B+C)	25.38	(2.52)
Cash and cash equivalents at the beginning of the year	3.41	5.93
Cash and cash equivalents at the end of the year	28.80	3.41

For JFL Life Sciences Limited



Smiral A. Patel
Director

DIN : 00769486

Dated : 14, November 2024

Place : Ahmedabad



JFL Life Sciences Limited

CIN : L24230GJ2010PLC060417

Reg Office :- 309, SATYAM MALL, OPP. SAMAN COMPLEX, NR. VISHWESHWAR MAHADEV MANDIR, SETTELITE, AHMEDABAD 380015

Tele No. +91-93772 95575, Email id :- info@jfllifesciences.com, www.jfllifesciences.com

STATEMENT OF ASSETS AND LIABILITIES AS AT 30TH SEPTEMBER, 2024

(Rs. In Lakhs)

PARTICULARS.	AS AT 30 Sept 2024	AS AT 31 Mar 2024
	AUDITED	AUDITED
EQUITY AND LIABILITIES.		
Shareholders' funds		
Equity share capital	1,099.84	1,099.84
Reserves and surplus	2,791.01	2,457.70
Sub-total- Shareholder's funds	3,890.85	3,557.54
NON CURRENT LIABILITIES.		
Deferred Tax Liabilities.	-	-
Long Term Borrowing	72.00	98.07
Long term provisions	11.24	10.44
Sub-total- Non Current Liabilities	83.24	108.51
CURRENT LIABILITIES.		
Short Term Borrowing	976.57	471.16
Trade payables		
- Total outstanding dues of micro and small enterprises	-	-
- Total outstanding dues of creditors other than micro and small enterprises	2,560.43	980.89
Short Term Provisions	108.34	170.17
Other current liabilities	824.54	375.91
Sub-total-Current Liabilities	4,469.88	1,998.12
TOTAL	8,443.97	5,664.17
ASSETS.		
Non-current assets		
Property, plant and equipment		
Tangible assets	1,216.16	1,247.41
Deferred Tax Assets	9.21	12.17
Other Non Current Assets	-	40.70
Long-term loans and advances	52.91	50.74
Sub-total- Non Current Assets	1,278.28	1,351.02
Current assets		
Inventories	1,824.42	1,583.33
Trade receivables	5,000.86	2,515.04
Cash and cash equivalents	28.80	3.41
Short-term loans and advances	311.62	208.64
Other current assets	-	2.73
Sub-total- Current Assets	7,165.69	4,313.15
TOTAL	8,443.97	5,664.17

For JFL Life Sciences Limited



Smiral A. Patel

Director

DIN : 00769486

Dated : 14, November 2024

Place : Ahmedabad





JFL LIFE SCIENCES LIMITED

November 14, 2024

To
The General Manager (Listing)
National Stock Exchange of India Limited
5th Floor, Exchange Plaza,
Plot No. c/1, G Block, Bandra-Kurla Complex, Bandra (East)
Mumbai-400051

Respected Sir(s),

**SUB: - DECLARATION ON UNMODIFIED OPINIONS UNDER REGULATION 33(3)(d) OF SEBI
(LODR) REGULATIONS, 2015**

NSE SYMBOL: JFLIFE; ISIN: INE0LA901015

Pursuant to regulation 33 of SEBI (LODR) Regulations, 2015, we hereby confirm and declare that the Statutory Auditors M/s Doshi Doshi & Co., Chartered Accountants (FRN: 153683W) has issued Audit Report in respect of Standalone Financial results for the Half Year ended September 30, 2024 with unmodified and unqualified opinion.

This is for your kind information and records.

Thanking You.

Yours Truly,

For JFL LIFE SCIENCES LIMITED

SMIRAL ASHWINKUMAR PATEL
Managing Director
DIN: 00769486